

Corporate Presentation

May 2024

A Rare Approach to Therapeutics

NasdaqGS: ZVRA



Cautionary Note Regarding Forward-Looking Statements



This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue," "could," "intend," "target," "predict," or the negative versions of those words or other comparable words or expressions, although not all forward-looking statements contain these identifying words or expressions. Forward-looking statements are not guarantees of future actions or performance. These forwardlooking statements include statements regarding the promise and potential impact of our preclinical or clinical trial data, including without limitation the timing and results of any clinical trials or readouts, our anticipated financial performance, our industry, our intellectual property, business strategy, plans, goals and expectations concerning our market position, future operations, the timing or results of any Investigational New Drug applications and NDA submissions, including the resubmission of the New Drug Application (NDA) for arimoclomol, communications with the FDA, the potential uses or benefits of arimoclomol, KP1077, SDX or any other product candidates for any specific disease indication or at any dosage, the potential benefits of any of Zevra's product candidates, the success or timing of the launch or commercialization of any products or related sales milestones, and our strategic and product development objectives. These forward-looking statements are based on information currently available to Zevra and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors including those discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on April, 2024, our quarterly report on Form 10-Q for the period ended March 31, 2024, filed on May 9, 2024, and in our other filings with the SEC could cause actual results, performance, or achievements to differ materially from those indicated by the forward-looking statements made herein.

While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to this presentation.

This presentation also may contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Becoming a Leading Rare Disease Company



Focused on Key Pillars for Strategic Growth

Our Mission:

Bringing life-changing therapeutics to people living with rare diseases Experienced team with rare disease expertise

Gr an

Growing pipeline with potential to bring new products and deliver value for patients

Experienced Team with Rare Disease Expertise





Neil F. McFarlane CEO and President



Adrian W. Quartel, MD FFPM Chief Medical Officer



Joshua Schafer Chief Commercial Officer & EVP of BD

RARE DISEASE EXPERIENCE



PRODUCT LAUNCH EXPERIENCE



Christal Mickle Chief Development Officer & Co-Founder



R. LaDuane Clifton, CPA CFO, Secretary & Treasurer



Sven Guenther, Ph.D. Chief Scientific Officer

i hiola*E*





EVENITY[®] (romosozumab-aggg) injection 105 mg/1.17 mL

GOCOVR

(amantadine) extended release capsules

68.5 mg | 137 mg

OLPRUVA (sodium phenylbutyrate) for oral suspension



nolbam



XOSPATA gilteritinib 40mg tablets



(cholic acid) capsules




Establishing Zevra as a Rare Disease Company Through Robust Advocacy Partnership





Diversified Portfolio with Potential to Bring New Products and Deliver Value for Patients





Certain products may be subject to royalty obligations, details and required disclosures are available in our SEC filings or on our website: <u>www.zevra.com</u>. 1. Data generated from this trial will be analyzed alongside the Phase 2 IH data to support clinical development of both narcolepsy and IH programs; 2. Zevra partnered asset



Commercial Excellence to Ensure Patient Access

Launch Excellence to Ensure Patient Access to Rare Disease Therapies



Overlap in prescribers and centers of excellence for OLPRUVA[®] and arimoclomol allow for efficient team approach




Sales Specialists calling on prescribing physicians and Centers of Excellence Patient Reimbursement Services to assist patients navigate reimbursement and treatment journey *Marketing* team to identify appropriate patients and product positioning in treatment landscape Account Management & Contracting team to ensure market access and contracting with payors Medical Affairs and Patient Advocacy team to work with Key Opinion Leaders and Advocacy Groups to advance scientific knowledge, and patient care

Urea Cycle Disorders Cause Hyperammonemia, Leading to Brain Damage or Death



OLPRUVA® is a nitrogen scavenger that removes excess ammonia



ARG, arginase; AS, argininosuccinate synthetase; ASL, argininosuccinate lyase; ATP, adenosine triphosphate; CoA, coenzyme A; CPS1, carbamoyl phosphate synthetase-1; NAG, N-acetylglutamate; NAGS, N-acetylglutamate synthetase; ORNT1, ornithine transporter; OTC, ornithine transcarbamylase.

- Defect in one of the 6 enzymes or 2 transporters in the urea cycle leads to accumulation of ammonia
- A clinical hallmark of UCDs is hyperammonemic crises (HAC)
- Elevated ammonia levels can be neurotoxic, leading to neurocognitive damage, neurocognitive impairment and even death, if untreated
- Duration and severity of HAC correlates with brain damage, often requiring emergency visits and hospitalization


Unmet Need in Urea Cycle Disorders



Poor treatment adherence can lead to neurocognitive damage, coma and even death

Orphan Designation

- US Incidence: 1 in 35,000 births¹
- US Prevalence:
 - Approximately 1 in 100,000¹
 - ~1,100 patients diagnosed²
 - >800 treated²
- About 80% of patients have mutations in either CPS, OTC or AS enzymes³



United States (U.S.) Market

^{1.} https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364413/

^{2.} HealthVerify Payer Claims data analysis 2021

^{3.} carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)

^{4.} Enns GM, Porter MH, Francis-Sedlak M, Burdett A, Vockley J. 2019

OLPRUVA® Designed to Address Unmet Needs in Treatment of UCDs



Unique formulation in single-dose envelopes for "ammonia control on the go"



UNIQUE FORMULATION DRIVES PALATABILITY AND ADHERENCE

- Novel formulation of phenylbutyrate
- Dual-coated formulation delays release in water for up to 5 minutes, rapidly dissolves in stomach
- Convenient, single-dose envelopes



FDA-APPROVED FOR LONG-TERM MANAGEMENT¹

- Adjunctive therapy to standard of care
- Long-term management of adults and children
- UCDs involving deficiencies of CPS, OTC, AS¹

COMPETITIVE ADVANTAGE

- Physicians attribute improved • adherence to:
 - Better palatability
 - Less odor
 - Ease of administration
- Patent protection through 2036
- Current market estimated \$350M •

OLPRUVA helps the body get rid of excess nitrogen to help avoid dangerous buildup of ammonia

1. OLPRUVA is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients weighing 20 kg (44 pounds) or greater and with a body surface area (BSA) of 1.2 m2 or greater, with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Product Insert can be found at https://olpruva.com/wp-content/uploads/OLPRUVA-Prescribing-Information.pdf

Important safety information can be found at https://olpruva.com/#ImportantSafetyInformation




Growing Pipeline in Rare Diseases

Niemann-Pick Disease Type C is a Neurodegenerative Lysosomal Storage Disorder



Cholesterol buildup leads to cell death; arimoclomol may enhance cholesterol metabolism through improved lysosomal function



- NPC gene mutations produce abnormal, absent or non-functional NPC proteins⁴
- Progressive lipid accumulation and cellular impairment leads to cell death and ultimately organ dysfunction in the spleen, liver and brain
- Disease results in impairment and loss of cognition, speech, swallow ability, fine motor skills and ambulation
- Heterogenous onset and rate of progression, always fatal

NPC, Niemann-Pick disease type C.

1. Carstea ED et al. Science. 1997;277:228-231. 2. Platt FM et al. Annu Rev Genomics Hum Genet. 2014;15:173-194. 3. Ingemann L, Kirkegaard T J Lipid Res. 2014;55:2198-2210. 4. Geberhiwot T, et al. Orphanet J Rare Dis. 2018 Apr 6;13(1):50.

No Approved NPC Treatments in the U.S.



Ultra-rare, relentlessly progressive and fatal neurodegenerative disease

Orphan Designation

- Incidence: ~1 in 130,000 live births¹
- Prevalence:
 - 1,800 patients estimated in EU and US
 - 900 patients estimated in US²
 - ~300 US patients currently diagnosed or treated²

Significant Unmet Need

- Neurocognitive decline adversely impacts daily living
- Irreversible and fatal disease
- Mean age of death is 13 years²
- No approved treatments exist in the U.S.


2. Burton et.al., Molecular Genetics and Metabolism Volume 134, Issues 1-2, September-October 2021, Pages 182-187

^{1.} https://link.springer.com/article/10.1186/1750-1172-5-16

Arimoclomol is Positioned to Become First-Line Treatment for NPC Patients



Evidence indicates that arimoclomol acts on multiple fronts to help reduce lipid build-up in cells with improved lysosomal function



Synergies and scale with Olpruva customer-facing team supporting both launches

1. Mengel E et al. J Inherit Metab Dis. 2021 Nov;44(6):1463-1480. 2. 4-year open-label extension of Phase 2/3 study

Vascular Ehlers-Danlos Syndrome Impairs Connective Tissue and Leads to Vascular Ruptures



Celiprolol designed to reduce the mechanical stress on collagen fibers within the arterial wall




Figure adapted from Omar R, et al. Matrix Biol Plus. 2021 Nov 9;12:100090.

- VEDS (Ehlers-Danlos Syndrome type IV) is the severe subtype:
 - Characterized by aneurysms, dissections and/or ruptures
 - Large and medium sized arteries
 - Hollow organs (e.g., gastrointestinal, uterine)
- Autosomal dominant (50%); spontaneous mutations (50%)
- Diagnosed by clinical symptoms and confirmed by presence of mutations in the COL3A1 gene
- Events occur in 25% of patients before the age of 20, and 90% by the age of 40
- The median survival age is 51 years, with arterial rupture being the most common cause of sudden death¹

Unmet Need in VEDS



Mutation in COL3A1 gene impairs connective tissue and leads to vascular ruptures

Orphan Designation

- Incidence: 1 in 50,00 to 200,000 people¹
- Prevalence 7,500 diagnosed patients in U.S.²

Significant Unmet Need

- No approved options in the U.S.
- Current treatment is focused on surgical intervention
- Celiprolol has become the primary treatment for VEDS patients in several European countries³


1. <u>https://www.orpha.net</u>

2. Estimate based on an analysis of diagnosed vEDS patients from the Truven MarketScan® database and U.S. population data.

3. FightvEds.org

Celiprolol is a Selective Adrenergic Modulator for SEVRA Potential Treatment of Patients with COL3A1+ VEDS

Phase 3 primary endpoint: time to first occurrence of primary cardiac or arterial clinical event




Idiopathic Hypersomnia (IH) Causes Excessive Daytime Sleepiness, Sleep Inertia and Brain Fog




KP1077 may provide optimal exposure of methylphenidate to better address these unmet needs

Idiopathic Hypersomnia Severity Scale



- 14 questions on a scale of 0 to 3 or 0 to 4, totaling 50 points
- Higher scores, indicate more severe/frequent symptoms¹
- Minimal Clinically Important Difference (MCID) of 4 points





- 8 questions on a scale of 0 to 3, totaling 24 points⁴
- Higher scores, indicate more severe daytime sleepiness
- 2- to 3-point change is considered MCID in sleep disorders⁵

- IH is a rare, debilitating, chronic neurologic disorder with an unknown pathophysiology
- Characterized by excessive daytime sleepiness (EDS)
- Excessively long sleep times
- Sleep inertia or difficulty waking
- Long and unrefreshing naps³
- Brain fog, memory problems, errors in habitual activities, mind blank and attention problems

*Idiopathic Hypersomnia Severity Scale is a self-report instrument designed to measure the severity of key symptoms of hypersomnolence

1. Dauvilliers Y, Evangelista E, Barateau L, et al. Measurement of symptoms in idiopathic hypersomnia: the Idiopathic Hypersomnia Severity Scale. Neurology. 2019;92(15):e1754-e1762.

- 2. Rassu AL et al. Idiopathic hypersomnia severity scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. J Clin Sleep Med. 2022;18(2):617-629.
- 3. ~25% of patients "long sleepers," >10hrs.

4. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540-545

5. Patel S, et al. The Epworth Sleepiness Scale: Minimum Clinically Important Difference in Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2018 Apr 1;197(7):961-963. doi: 10.1164/rccm.201704-0672LE.

Unmet Need in Idiopathic Hypersomnia



IH is a rare, debilitating, chronic neurologic disorder with an unknown pathophysiology

Orphan Designation

- Incidence: 10.3 per 100,000 people in the US¹
- Prevalence: ~37,000 patients diagnosed²
- Total population may be much larger

Current Treatments Don't Address Needs

- Patients rated current medication effectiveness as poor (5.4 on a 10-point scale)³
- Tolerable stimulant treatment doses currently available are inadequate to treat brain fog
- Comorbidities complicate treatment (cardiovascular and patient demographics)
- Potential DDIs with contraceptives, antidepressants, antihistamines

1. https://doi.org/10.1093/sleep/zsy061.624

2. https://www.sleepcountshcp.com/what-is-idiopathic-hypersomnia

3. https://www.sleepcountshcp.com/idiopathic-hypersomnia-treatment-options

KP1077 is a Novel Approach to Treating IH



Unique PK profile and dosing regimen designed to address EDS and sleep inertia





KP1077 FOR IH

- Proprietary prodrug of d-MPH
- Potential to address primary IH symptoms
- Two dosing regimens being explored
 - Once daily at bedtime
 - 2x daily: once in the morning and once at bedtime
- Full data package from Ph. 2 trial to be presented at SLEEP 2024 in early June

IMPROVED SAFETY & TOLERABILITY OVER EXISTING TREATMENTS

- Unique pharmacokinetic profile to overcome key symptoms
- Greater tolerability and lower cardiovascular effects
- No DDI potential with hormonal contraceptives; antidepressants

REGULATORY & IP ADVANTAGES

- Orphan Drug designation in IH
- Solid IP through 2037 and potentially beyond
- Less abuse potential (SDX is designated Schedule IV controlled substance by DEA in the U.S.)¹
- Planning for an End-of-Phase 2 meeting with the FDA in Q3

Focused on Key Pillars for Strategic Growth

Our Mission:

Bringing life-changing therapeutics to people living with rare diseases



Rare Disease Team

- Strong experience in rare disease commercial launches
- Track record of success in drug development and in overcoming complex regulatory challenges

Commercial Excellence

- Growing capabilities in-line with vision for a patient-minded approach
- Immediate focus on driving awareness and demand for OLPRUVA[®]
- Preparing for arimoclomol launch

Growing Pipeline

SZEVRA

THERAPEUTICS

- Arimoclomol: PDUFA Sep 21, 2024
- Celiprolol: Ongoing Ph. 3 program
- KP1077: Ph. 2 trial complete; full data package to be presented SLEEP 2024; Planning for EOP2 meeting in Q3 2024

Financial strength to execute on our key priorities

Thank You



